ArticleCJC open2026
Integrating Biomarkers and Hemodynamics for 1-Year Mortality Risk Stratification in Transcatheter Tricuspid Intervention.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers of systemic disease burden and outcomes after transcatheter tricuspid edge-to-edge repair.BMC cardiovascular disorders · 2026Article
- Comparative prognostic performance of risk scores for 12-month mortality and rehospitalization after transcatheter tricuspid valve intervention.Annals of cardiothoracic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter tricuspid interventions for severe tricuspid regurgitation are being used increasingly, yet many patients present at an advanced stage, when clinical benefit is limited. The conventional biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) often fails to reflect systemic organ injury or right-sided hemodynamics. We hypothesized that systemic biomarkers combined with invasive haemodynamic data improve risk stratification for 1-year mortality after transcatheter tricuspid regurgitation intervention. Methods: In this prospective, single-centre cohort, preprocedural blood samples for biomarker assessment (growth differentiation factor-15 [GDF-15], soluble urokinase plasminogen activator receptor [suPAR], heart-type fatty acid-binding protein [H-FABP], soluble suppression of tumorigenicity-2 [sST2}, NT-proBNP) and right atrial (RA) pressure were obtained in patients undergoing transcatheter tricuspid repair or valve implantation. Incremental prognostic value was assessed by adding RA pressure to biomarker-based models. Predictive performance for 1-year all-cause mortality was evaluated using receiver operating characteristic analyses. Optimal cutoffs were derived by Youden's index, and survival was compared using Kaplan-Meier analysis and log-rank testing. Results: Among 100 patients (mean age, 80.7 ± 6.7 years; 48% male), 22 (22%) died within 1 year. The cohort showed advanced disease and a high comorbidity burden. GDF-15 demonstrated the highest prognostic accuracy (area under the curve [AUC] 0.795, 95% confidence interval [CI] 0.675-0.915; Conclusions: In patients undergoing transcatheter tricuspid intervention, GDF-15 and suPAR outperform NT-proBNP in predicting 1-year mortality. Integration of RA pressure further refines risk stratification and may aid patient selection and the timing of intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.